Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

66.30 -0.09 (-0.14%)
Streaming Delayed Price Updated: 10:52 AM EDT, Jul 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Rhythm Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
8 Analysts Have This To Say About Rhythm Pharmaceuticals
Via Benzinga
Here's How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years
Via Benzinga
12 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know
Via Benzinga
RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM) – A Strong Growth Candidate Meeting Minervini’s Criteria
RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM) meets Minervini’s Trend Template with strong technicals and high revenue growth, making it a candidate for growth investors. 
Via Chartmill
Rhythm Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings)
Via Benzinga
Earnings Scheduled For May 7, 2025
Via Benzinga
These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio?
Top mid-cap stock performers last week: AGL, RXRX, CERT, AVAV, STRL, ORLA, IAG, SBSW, LOAR, RYTM, TLX. High gains due to positive news and macro uncertainty. 
Via Benzinga
Assessing Rhythm Pharmaceuticals: Insights From 10 Financial Analysts
Via Benzinga
Earnings Scheduled For February 26, 2025
Via Benzinga
Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Ross Stores To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Rhythm Pharmaceuticals Stock Rises On Positive Trial Data From Therapy In Treating Hypothalamic Obesity: Retail, Analysts Get More Bullish
CEO David Meeker said the company is preparing to submit a supplemental New Drug Application to the FDA and a Type II variation request to the European Medicines Agency in the third quarter of 2025. 
Via Stocktwits
Topics Government
7 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know
Via Benzinga
Forecasting The Future: 14 Analyst Projections For Rhythm Pharmaceuticals
Via Benzinga
A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 13 Analysts
Via Benzinga
Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder
Rhythm's Phase 3 trial shows setmelanotide significantly reduced BMI in rare hypothalamic obesity without new safety concerns over 52 weeks. 
Via Benzinga
Analyst Expectations For Rhythm Pharmaceuticals's Future
Via Benzinga
Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential
Rhythm Pharmaceuticals targets rare obesity disorders with its drug Imcivree, showing strong growth in sales and potential for significant market expansion 
Via Benzinga
What's Next: Rhythm Pharmaceuticals's Earnings Preview
Via Benzinga
Critical Insights From Rhythm Pharmaceuticals Analyst Ratings: What You Need To Know
Via Benzinga
Navigating 5 Analyst Ratings For Rhythm Pharmaceuticals
Via Benzinga
What 4 Analyst Ratings Have To Say About Rhythm Pharmaceuticals
Via Benzinga
A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 4 Analysts
Via Benzinga
Analyst Expectations For Rhythm Pharmaceuticals's Future
Via Benzinga
RYTM Stock Earnings: Rhythm Pharmaceuticals Beats EPS, Misses Revenue for Q2 2024
RYTM stock results show that Rhythm Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
The 3 Best Nasdaq Stocks to Buy in May 2024
Although it’s typically the season for selling, shifting market conditions call for the best Nasdaq stocks to buy in May. 
Via InvestorPlace
RYTM Stock Earnings: Rhythm Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
RYTM stock results show that Rhythm Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Jim Cramer Is 'Willing To Let This Pharma Stock Catch Fire,' Advises Not To Sell McKesson
The "Mad Money" host recommended buying some Marvell Technology, and then wait until under $60 to buy the rest. 
Via Benzinga
5 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know
Via Benzinga
Analyst Expectations For Rhythm Pharmaceuticals's Future
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.